DOI: 10.7241/ourd.20123.52 article in PDF
Our Dermatol Online. 2012; 3(3): 227
Date of submission: 15.01.2012 / acceptance: 28.02.2012
Conflicts of interest: None
MAYERSON’S PHENOMENON IN A CUTANEOUS NEUROFIBROMA
Iffat Hassan, Peerzada Sajad
Department of Dermatology, STD & Leprosy, Government Medical College Srinagar, University of Kashmir, J&K, India
Corresponding author: Iffat Hassan, Ass. Prof. e-mail:hassaniffat@gmail.com
How to cite an article: Hassan I, Sajad P. Mayerson’s phenomenon in a cutaneous neurofibroma. Our Dermatol Online 2012; 3(3): 227.
We report the case of a 45year old normotensive, nondiabetic, policeman, smoker who presented with a two week’s history of red crusted scaly lesion around a skin coloured pedunculated growth over the back. There was associated history of severe itching,but no history of trauma, pain, bleeding, application of any substance or any constitutional features. Examination revealed a well-defined annular moist erythematous scaly crusted plaque around a skin coloured nodule (neurofibroma) which had been present on the back for the past 30 years. There were multiple neurofibromas present over the back and abdomen. Besides routine testing, punch biopsy was taken for histopathological examination. Histopathology of the specimen showed spongiosis with lymphocytic infiltrate and few eosinophils which confirmed the diagnosis of mayerson’s phenomenon. Topical steroid (clobetasol propionate,l/a b.d) and an antihistaminic (levocetrizine5m b.d) was prescribed and the condition resolved in a week (Fig 1, 2).
![]() Figure 1. Mayerson’s phenomenon
|
![]() Figure 2. 1 week after the application of topical steroid
|
Discussion
Mayerson’s phenomenon is an uncommon clinical condition that is characterised by an eczematous halo surrounding a pre-existing melanocytic naevus, and numerous other lesions like molluscum contagiosum, skin tags seborrheic warts and other elevated skin lesions. The etiology of this condition is unknown. It is hypothesised that it occurs because of the interaction between CD4+T lymphocytes and increased expression of ICAM-1.
Comments are closed.